Financial Report: Johnson & Johnson 1Q

Johnson & Johnson

1Q Revenues: $17.4 billion (-4%)

1Q Earnings: $4.3 billion (-9%)

Comments: Pharmaceutical sales were $7.7 billion, down 7% in the quarter. RISPERDAL CONSTA sales were down 18% to $254 million. VELCADE sales were down 17% to $339 million. OLYSIO/ SOVRIAD sales were down 34% to $234 million, due to generic completion. REMICADE sales were $1.6 billion, down 0.6%. STELARA sales were $549 million, up 20%. CONCERTA sales were $224 million, up 49%. SUSTENNA/XEPLION sales were $441 million up 10%. During the quarter, the FDA approved IMBRUVICA (ibrutinib) for the treatment of Waldenström’s Macroglobulinemia and for PREZCOBIX (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of HIV-1. Worldwide Consumer sales were $3.4 billion in the quarter, down 5%.